20 completed, 3 active not recruiting, 3 not yet recruiting, 3 recruiting. 15 Phase 1, 10 Phase 3, 4 Phase 2.
By phase and status
Follow BI 456906: new trials by email Literature Review of BI 456906 trials Research Report on BI 456906
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|
SYNCHRONIZE®-START- A Study to Test Whether Survodutide Helps People Living With Overweight or Obesity Who do Not Have Diabetes to Lose Weight
Survodutide - Obesity | Phase 3 | Not yet recruiting | 350 | 2026-11-07 | 2026-10-27 |
SYNCHRONIZE®-HERA: A Study to Test Whether Survodutide Helps Women Who Are Living With Overweight or Obesity and Are Going Through or Have Finished Menopause, to Lose Weight
Survodutide, Placebo - Obesity | Phase 3 | Not yet recruiting | 600 | 2026-10-31 | 2026-10-30 |
A Study to Compare How 2 Different Formulations of Survodutide Are Taken up in the Body When Given by Injection in Healthy Men and Women With and Without Overweight or Obesity
Survodutide formulation A, Survodutide formulation B2 - Healthy, Obesity | Phase 1 | Active not recruiting | 44 | 2026-09-02 | 2026-10-28 |
A Study to Test Whether Survodutide Helps People With Type 2 Diabetes Control Their Blood Sugar
Placebo, Survodutide - Type 2 Diabetes | Phase 3 | Recruiting | 600 | 2026-08-24 | 2026-10-29 |
A Study in Healthy People or Otherwise Healthy With Overweight or Obesity to Compare 2 Formulations of Survodutide Given in Different Ways, Either as a Pre-filled Syringe or a Pen-like Injector
Survodutide formulation A, Survodutide formulation B2 - Healthy, Obesity | Phase 1 | Completed | 56 | 2026-03-03 | 2026-06-15 |
Albuminuria Reduction Study With Survodutide Treatment in Kidney Disease
Survodutide (BI 456906), Placebo - Chronic Kidney Disease | Phase 2 | Not yet recruiting | 120 | 2026-03-02 | 2025-10-03 |
A Study to Test Whether Survodutide Improves How the Body Uses Energy and Breaks Down Fat in People With Obesity
Survodutide, Semaglutide - Obesity | Phase 1 | Active not recruiting | 64 | 2025-03-26 | 2026-05-12 |
LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis
Survodutide, Placebo matching survodutide - Metabolic Dysfunction Associated Steatohepatitis | Phase 3 | Recruiting | 1590 | 2024-11-12 | 2026-10-28 |
A Study in People With Obesity to Test the Effects of BI 456906 Compared With Semaglutide on Glucagon Receptor Activity in the Liver
BI 456906, Semaglutide - Obesity | Phase 1 | Active not recruiting | 29 | 2024-11-01 | 2026-09-09 |
LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis
Survodutide, Placebo - Metabolic Dysfunction Associated Steatohepatitis (MASH), Liver Fibrosis | Phase 3 | Recruiting | 1800 | 2024-10-14 | 2026-10-28 |
A Study to Test Whether BI 456906 (Survodutide) Influences the Amount of Bupropion, Caffeine and Midazolam in the Blood in People With Overweight or Obesity
Survodutide, Bupropion, Caffeine - Overweight, Obesity | Phase 1 | Completed | 34 | 2024-10-01 | 2026-03-13 |
A Study to Test How BI 456906 is Taken up in the Blood of People With and Without Kidney Problems
BI 456906 - Healthy, Renal Impairment | Phase 1 | Completed | 42 | 2024-05-15 | 2026-03-13 |
A Study in People With Overweight or Obesity to Test How BI 1820237, BI 456906, or a Combination of Both Affects Brain Activity
BI 456906, BI 1820237, Placebo for BI 1820237 - Obesity | Phase 1 | Completed | 23 | 2024-04-30 | 2025-03-12 |
A Study to Test Whether Multiple Doses of BI 456906 Have an Effect on Cardiac Safety in People With Overweight or Obesity
BI 456906, Placebo to BI 456906, Moxifloxacin - Overweight, Obesity | Phase 1 | Completed | 110 | 2024-03-13 | 2026-03-13 |
A Study to Test Whether Survodutide (BI 456906) Helps Chinese People Living With Overweight or Obesity to Lose Weight
survodutide, Placebo matching BI 456906 - Obesity, Overweight | Phase 3 | Completed | 307 | 2024-02-06 | 2026-04-30 |
A Study to Test Whether Survodutide Helps Japanese People Living With Obesity Disease
Survodutide, Placebo matching survodutide - Obesity | Phase 3 | Completed | 274 | 2024-01-16 | 2026-04-30 |
A Study in Women With Overweight or Obesity to Test Whether Different Doses of BI 456906 Influence the Amount of a Contraceptive in the Blood
BI 456906, Microgynon® - Healthy | Phase 1 | Completed | 32 | 2023-12-21 | 2025-04-16 |
A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who Also Have Diabetes to Lose Weight
Survodutide, Placebo - Obesity, Diabetes Mellitus, Type 2 | Phase 3 | Completed | 755 | 2023-11-27 | 2026-08-06 |
A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who do Not Have Diabetes to Lose Weight
survodutide, Placebo - Obesity | Phase 3 | Completed | 726 | 2023-11-25 | 2026-03-12 |
A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE™ - CVOT)
survodutide, Placebo - Obesity | Phase 3 | Completed | 5530 | 2023-11-20 | 2026-10-29 |
Showing 20 of 29. Sign in to see all of them.
Conditions studied
Obesity (18) · Diabetes Mellitus, Type 2 (3) · Overweight (3) · Liver Cirrhosis (1) · Liver Diseases (1) · Non-alcoholic Fatty Liver Disease (1) · Renal Insufficiency (1) · Renal Insufficiency, Chronic (1)
Sponsors
Boehringer Ingelheim (28) · University Medical Center Groningen (1)
Countries
Germany (18) · United States (13) · New Zealand (10) · Australia (9) · Canada (9) · Netherlands (9) · Poland (9) · United Kingdom (9) · Belgium (8) · China (8) · Japan (8) · South Korea (8) · Hungary (7) · Czechia (6) · Spain (6)
Results publications
PMID 36527386, PMID 42331726, PMID 38095657, PMID 38330987, PMID 38847460, PMID 38857788, PMID 39453356, PMID 39821928, PMID 41187967, PMID 41216778, PMID 42219222, PMID 42253238, PMID 42599381, PMID 42820639
NIH funding
2023 (3), 2017 (1), 2018 (1), 2019 (1), 2025 (1)